Novo Nordisk to Sell Wegovy Weight‑Loss Pill in U.S. to Self‑Pay Patients Starting at $149/Month

Denmark‑based pharmaceutical company Novo Nordisk has announced that from January 5, 2026 it will begin selling its newly FDA‑approved Wegovy weight‑loss pill directly to self‑pay patients in the United States. The move comes after the U.S. Food and Drug Administration granted approval to the oral formulation of Wegovy on December 22, 2025. Under the initial pricing structure, Wegovy pills at 1.5 mg and 4 mg doses will be offered at $149 per month. Higher doses—9 mg and 25 mg—will be priced at $299 per month. Novo Nordisk also plans to adjust the price of the 4 mg dose to $199 per month beginning April 15, 2026. The semaglutide pills contain the same active ingredient as the company’s injectable Wegovy and Ozempic treatments, and will be marketed under the Wegovy brand. Novo Nordisk already has experience with oral semaglutide through Rybelsus, a diabetes medication. The launch of the oral weight‑loss pill is seen as a strategic step to compete with rivals like Eli Lilly and expand access for patients who pay out‑of‑pocket without insurance coverage. #NovoNordisk #Wegovy #WeightLossPill #HealthcareNews #SlimScan #GrowthStocks #CANSLIM